|
|
ARNA Discussion Board
|
|
||
Re: 300 a share?Stop blaming Belviq failure on Eisai. Belviq was ineffective, overpriced and lacked insurance coverage. Etrasimod and Ralenipag both appear to be best in class for their indications so insurance coverage shouldn't become an issue. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
45209 | Re: 300 a share? | deputyretired48047 | 12 | 10/12/2019 1:13:34 PM |
45222 | Re: 300 a share? | georgegrin | 0 | 10/12/2019 5:21:03 PM |